Omeros (NASDAQ:OMER) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $36.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Down 2.1 %

Shares of Omeros stock opened at $6.18 on Wednesday. Omeros has a 52-week low of $3.00 and a 52-week high of $13.60. The firm’s 50 day moving average price is $7.43 and its 200-day moving average price is $8.12. The company has a market cap of $360.33 million, a P/E ratio of -2.68 and a beta of 2.42.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter last year, the business posted ($0.15) EPS. As a group, equities research analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Vanguard Group Inc. boosted its position in shares of Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock worth $26,610,000 after buying an additional 95,599 shares during the period. Nomura Holdings Inc. grew its stake in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after purchasing an additional 430,932 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Omeros by 2.2% during the 1st quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after buying an additional 3,321 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Omeros in the fourth quarter valued at $1,488,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.